Re-examining the role of hematopoietic stem cell transplantation in relapsed large B-cell lymphoma in the era of chimeric antigen receptor (CAR) T-cell therapy

被引:0
作者
Moyo, Tamara K. [1 ]
Vaidya, Rakhee [2 ]
机构
[1] Atrium Hlth, Levine Canc Inst, Dept Hematol Oncol & Blood Disorders, Charlotte, NC 28203 USA
[2] Atrium Hlth Wake Forest Baptist, Comprehens Canc Ctr, Dept Hematol & Oncol, Winston Salem, NC USA
来源
FRONTIERS IN ONCOLOGY | 2024年 / 14卷
关键词
relapsed large B-cell lymphoma (LBCL); CAR T-cell therapy; autologous stem cell transplant (ASCT); tisagenlecleucel; axicabtagene ciloleucel; lisocabtagene maraleucel; BONE-MARROW-TRANSPLANTATION; CHEMOTHERAPY PLUS RITUXIMAB; HIGH-DOSE THERAPY; PROGNOSTIC VALUE; ELDERLY-PATIENTS; LISOCABTAGENE MARALEUCEL; OUTCOMES; CHOP; IMPACT; TRIAL;
D O I
10.3389/fonc.2024.1397186
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Historically, salvage chemoimmunotherapy with consolidative autologous hematopoietic stem cell transplantation (ASCT) was the only potentially curative therapeutic option for patients with relapsed/refractory large B-cell lymphoma (LBCL). Treatment options were few and outcomes poor for patients whose lymphoma failed to respond to salvage chemotherapy/ASCT and for patients not eligible for ASCT. The approval of chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory LBCL revolutionized the treatment landscape with unprecedented response rates and durability of responses. As a result, earlier intervention with CAR T-cell therapy has been explored, and the enthusiasm for CAR T-cell therapy has overshadowed ASCT. In this article, we will review the data available for ASCT and CAR T-cell therapy in relapsed LBCL and will examine the role for ASCT in relapsed/refractory LBCL in the era of CAR T-cell therapy.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study
    Abramson, Jeremy S.
    Solomon, Scott R.
    Arnason, Jon
    Johnston, Patrick B.
    Glass, Bertram
    Bachanova, Veronika
    Ibrahimi, Sami
    Mielke, Stephan
    Mutsaers, Pim
    Hernandez-Ilizaliturri, Francisco
    Izutsu, Koji
    Morschhauser, Franck
    Lunning, Matthew
    Crotta, Alessandro
    Montheard, Sandrine
    Previtali, Alessandro
    Ogasawara, Ken
    Kamdar, Manali
    [J]. BLOOD, 2023, 141 (14) : 1675 - 1684
  • [2] Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
    Abramson, Jeremy S.
    Palomba, M. Lia
    Gordon, Leo I.
    Lunning, Matthew A.
    Wang, Michael
    Arnason, Jon
    Mehta, Amitkumar
    Purev, Enkhtsetseg
    Maloney, David G.
    Andreadis, Charalambos
    Sehgal, Alison
    Solomon, Scott R.
    Ghosh, Nilanjan
    Albertson, Tina M.
    Garcia, Jacob
    Kostic, Ana
    Mallaney, Mary
    Ogasawara, Ken
    Newhall, Kathryn
    Kim, Yeonhee
    Li, Daniel
    Siddiqi, Tanya
    [J]. LANCET, 2020, 396 (10254) : 839 - 852
  • [3] Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure
    Ayers, Emily C.
    Li, Shaoying
    Medeiros, L. Jeffrey
    Bond, David A.
    Maddocks, Kami J.
    Torka, Pallawi
    Hicks, Angel Mier
    Curry, Madeira
    Wagner-Johnston, Nina D.
    Karmali, Reem
    Behdad, Amir
    Fakhri, Bita
    Kahl, Brad S.
    Churnetski, Michael C.
    Cohen, Jonathon B.
    Reddy, Nishitha M.
    Modi, Dipenkumar
    Ramchandren, Radhakrishnan
    Howlett, Christina
    Leslie, Lori A.
    Cytryn, Samuel
    Faramand, Rawan
    Chavez, Julio C.
    Olszewski, Adam J.
    Liu, Yang
    Barta, Stefan K.
    Mukhija, Dhruvika
    Hill, Brian T.
    Ma, Helen
    Amengual, Jennifer E.
    Nathan, Sunita
    Assouline, Sarit E.
    Orellana-Nola, Victor M.
    Portell, Craig A.
    Chandar, Ashwin
    David, Kevin A.
    Giri, Anshu
    Hess, Brian T.
    Landsburg, Daniel J.
    [J]. CANCER, 2020, 126 (02) : 293 - 303
  • [4] Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303
    Bartlett, Nancy L.
    Wilson, Wyndham H.
    Jung, Sin-Ho
    Hsi, Eric D.
    Maurer, Matthew J.
    Pederson, Levi D.
    Polley, Mei-Yin C.
    Pitcher, Brandelyn N.
    Cheson, Bruce D.
    Kahl, Brad S.
    Friedberg, Jonathan W.
    Staudt, Louis M.
    Wagner-Johnston, Nina D.
    Blum, Kristie A.
    Abramson, Jeremy S.
    Reddy, Nishitha M.
    Winter, Jane N.
    Chang, Julie E.
    Gopal, Ajay K.
    Chadburn, Amy
    Mathew, Susan
    Fisher, Richard I.
    Richards, Kristy L.
    Schoder, Heiko
    Zelenetz, Andrew D.
    Leonard, John P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (21) : 1790 - +
  • [5] Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
    Bishop, M. R.
    Dickinson, M.
    Purtill, D.
    Barba, P.
    Santoro, A.
    Hamad, N.
    Kato, K.
    Sureda, A.
    Greil, R.
    Thieblemont, C.
    Morschhauser, F.
    Janz, M.
    Flinn, I
    Rabitsch, W.
    Kwong, Y-L
    Kersten, M. J.
    Minnema, M. C.
    Holte, H.
    Chan, E. H. L.
    Martinez-Lopez, J.
    Mueller, A. M. S.
    Maziarz, R. T.
    McGuirk, J. P.
    Bachy, E.
    Le Gouill, S.
    Dreyling, M.
    Harigae, H.
    Bond, D.
    Andreadis, C.
    McSweeney, P.
    Kharfan-Dabaja, M.
    Newsome, S.
    Degtyarev, E.
    Awasthi, R.
    del Corral, C.
    Andreola, G.
    Masood, A.
    Schuster, S. J.
    Jaeger, U.
    Borchmann, P.
    Westin, J. R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (07) : 629 - 639
  • [6] CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
    Coiffier, B
    Lepage, E
    Brière, J
    Herbrecht, R
    Tilly, H
    Bouabdallah, R
    Morel, P
    Van den Neste, E
    Salles, G
    Gaulard, P
    Reyes, F
    Gisselbrecht, C
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) : 235 - 242
  • [7] Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
    Crump, Michael
    Neelapu, Sattva S.
    Farooq, Umar
    Van den Neste, Eric
    Kuruvilla, John
    Westin, Jason
    Link, Brian K.
    Hay, Annette
    Cerhan, James R.
    Zhu, Liting
    Boussetta, Sami
    Feng, Lei
    Maurer, Matthew J.
    Navale, Lynn
    Wiezorek, Jeff
    Go, William Y.
    Gisselbrecht, Christian
    [J]. BLOOD, 2017, 130 (16) : 1800 - 1808
  • [8] Second Malignancies after Hematopoietic Stem Cell Transplantation
    Danylesko, Ivetta
    Shimoni, Avichai
    [J]. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2018, 19 (02)
  • [9] High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma
    Dean, Erin A.
    Mhaskar, Rahul S.
    Lu, Hong
    Mousa, Mina S.
    Krivenko, Gabriel S.
    Lazaryan, Aleksandr
    Bachmeier, Christina A.
    Chavez, Julio C.
    Nishihori, Taiga
    Davila, Marco L.
    Khimani, Farhad
    Liu, Hien D.
    Pinilla-Ibarz, Javier
    Shah, Bijal D.
    Jain, Michael D.
    Balagurunathan, Yoganand
    Locke, Frederick L.
    [J]. BLOOD ADVANCES, 2020, 4 (14) : 3268 - 3276
  • [10] Pretransplantation Positron Emission Tomography Scan Is the Main Predictor of Autologous Stem Cell Transplantation Outcome in Aggressive B-Cell Non-Hodgkin Lymphoma
    Derenzini, Enrico
    Musuraca, Gerardo
    Fanti, Stefano
    Stefoni, Vittorio
    Tani, Monica
    Alinari, Lapo
    Venturini, Filippo
    Gandolfi, Letizia
    Baccarani, Michele
    Zinzani, Pier Luigi
    [J]. CANCER, 2008, 113 (09) : 2496 - 2503